There is one clinical trial.
A randomized controlled pilot study on the safety & efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
Description: Proportion of patients with COVID-19 pneumonia progressed to critical illness in need for invasive mechanical ventilation.Measure: Primary endpoint: Disease Progression Time: 30 Days
Description: Improvement of Hypoxic index( PaO2 / FiO2) calculated dailyMeasure: Improvement in Hypoxic Index Time: From inclusion to 30 days follow up
Description: Hospital Length of stayMeasure: Hospital Length of Stay Time: From inclusion to 30 days follow up
Description: Days on mechanical ventilation for patients needing intubation & invasive mechanical ventilationMeasure: Days on invasive mechanical ventilation Time: From inclusion to 30 days follow up
Description: Difference in the median levels of serum IL-6, serum ferritin, CRP at the end of the follow up period between all groupsMeasure: Inflammatory Markers Time: From inclusion to 30 days
Description: Rate of viral clearance as monitored by SARS-COV-2 PCRMeasure: Viral clearance Time: From inclusion to 30 days
Description: Difference in the overall evaluation of pulmonary infiltrative (improving / deteriorating) as assessed by imaging (Chest X-ray or Non-contrast pulmonary CT)Measure: Radiological assessment Time: From inclusion to 30 days
Description: Rate of serious adverse events (SAEs)Measure: Safety of Imatinib Time: From inclusion to 60 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports